Acquisition of FemiClear and CUROXEN

Summary by AI BETAClose X

Venture Life Group PLC has announced the acquisition of the FemiClear and CUROXEN brands from OrganiCare Nature's Sciences, LLC for up to $28.0 million. In the twelve months ended March 31, 2026, these brands generated $12.1 million in net revenue, a 29.1% increase from the prior year, with gross profit of $7.5 million and contribution of $3.6 million. The acquisition, funded by existing cash resources, is expected to strengthen Venture Life's position in the US market and women's intimate health sector, with synergies anticipated from 2027 onwards. The total consideration includes an initial $23.0 million cash payment and up to $5.0 million in deferred consideration contingent on future trading results.

Disclaimer*

UK 100

Latest directors dealings